Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy conceptAlessandro Vitale, Francesco Paolo Russo, Andrea Casadei‐Gardini et al.|The Lancet Oncology|2023Cited by 184
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysisMaria Guarino, Andrea Casadei‐Gardini, Luca Viganò et al.|Digestive and Liver Disease|2018Cited by 61
<i>BRAF</i> mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastasesStéphane Benoist, Nathan Moreno-Lopez, Luca Viganò et al.|British journal of surgery|2019Cited by 42
Phase Ib clinical and pharmacological study of multiple schedules of pazopanib (P) and epirubicin (EPI) in patients with advanced solid tumors.Angelica Fasolo, Luca Gianni, C. Sessa et al.|Journal of Clinical Oncology|2010Cited by 1